Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 7/20 | 0.66 |
| ▸ | MAPK9 | P45984 | 7/20 | 0.66 |
| ▸ | CCNK | O75909 | 13/20 | 0.65 |
| ▸ | CDK12 | Q9NYV4 | 13/20 | 0.65 |
| ▸ | CDK7 | P50613 | 10/20 | 0.65 |
| ▸ | CCNH | P51946 | 10/20 | 0.65 |
| ▸ | CCNA2 | P20248 | 8/20 | 0.65 |
| ▸ | CDK2 | P24941 | 8/20 | 0.65 |
| ▸ | CDK9 | P50750 | 6/20 | 0.65 |
| ▸ | CDK13 | Q14004 | 6/20 | 0.65 |
| ▸ | CCNT1 | O60563 | 5/20 | 0.65 |
| ▸ | MNAT1 | P51948 | 7/20 | 0.62 |
| ▸ | CDK3 | Q00526 | 1/20 | 0.61 |
| ▸ | PIKFYVE | Q9Y2I7 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16653960 | 1.00 | MAPK8 (0.66) | MAPK8MAPK9CCNKCDK12CDK7 | |
| SCHEMBL18047386 | 0.91 | MAPK8 (0.55) | MAPK8MAPK9CCNKCDK12CDK7 | |
| SCHEMBL16653990 | 0.91 | MAPK8 (0.55) | MAPK8MAPK9CCNKCDK12CDK7 | |
| SCHEMBL18047395 | 0.86 | CDK7 (0.67) | MAPK8MAPK9CCNKCDK12CDK7 | |
| SCHEMBL18047397 | 0.86 | CDK7 (0.67) | MAPK8MAPK9CCNKCDK12CDK7 | |
| SCHEMBL18047396 | 0.86 | CDK7 (0.67) | MAPK8MAPK9CCNKCDK12CDK7 | |
| SCHEMBL21397218 | 0.86 | CDK7 (0.67) | MAPK8MAPK9CCNKCDK12CDK7 | |
| SCHEMBL18047398 | 0.86 | CDK7 (0.67) | MAPK8MAPK9CCNKCDK12CDK7 | |
| SCHEMBL21397213 | 0.86 | CDK7 (0.67) | MAPK8MAPK9CCNKCDK12CDK7 | |
| SCHEMBL16653803 | 0.85 | CDK12 (0.52) | MAPK8MAPK9CCNKCDK12CDK7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190292167-A1 | HETEROAROMATIC COMPOUNDS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | SYROS PHARMACEUTICALS INC (US) | 2019-09-26 | — | — | US | disclosed |
| US-20160264552-A1 | HETEROMAROMATIC COMPOUNDS USEFUL FOR THE TREATMENT OF PROLFERATIVE DISEASES | SYROS PHARMACEUTICALS INC (US) | 2016-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190292167-A1 | HETEROAROMATIC COMPOUNDS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | CDK7, CDK3, CDK17 | MAPK8 352/4885MAPK9 506/4885CCNK 10/4885 |
| US-20160264552-A1 | HETEROMAROMATIC COMPOUNDS USEFUL FOR THE TREATMENT OF PROLFERATIVE DISEASES | CDK7, CDK6, CDK3 | MAPK8 532/4885MAPK9 599/4885CCNK 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.